• Spyre Therapeutics approved options covering 11,138 shares for two non-executive employees on November 2, 2026, under its 2018 Equity Inducement Plan.
• The awards also include 3,195 restricted stock units.
• Stock options carry a 10-year term with a $95.51 exercise price.
• Options vest 25% on each employee's first start-date anniversary, then 1/48 monthly, subject to continuous service.
• RSUs vest 25% annually on anniversaries of the next November 15 on or after each employee's start date, subject to continuous service.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611061605PRIMZONEFULLFEED9869315) on November 06, 2026, and is solely responsible for the information contained therein.